Fetal acetylcholine receptor inactivation syndrome
A myopathy due to maternal antibodies

ABSTRACT

Background: Transient neonatal myasthenia gravis (TNMG) affects a proportion of infants born to mothers with myasthenia gravis (MG). Symptoms usually resolve completely within the first few months of life, but persistent myopathic features have been reported in a few isolated cases.

Methods: Here we report 8 patients from 4 families born to mothers with clinically manifest MG or mothers who were asymptomatic but had elevated acetylcholine receptor (AChR) antibody levels.

Results: Clinical features in affected infants ranged from a mild predominantly facial and bulbar myopathy to arthrogryposis multiplex congenita. Additional clinical findings included hearing impairment, pyloric stenosis, and mild CNS involvement. In all cases, antibodies against the AChR were markedly elevated, although not always specific for the fetal AChR γ subunit. There was a correlation between maternal symptoms; the timing, intensity, and frequency of maternal treatment; and neonatal outcome.

Conclusions: These findings suggest that persistent myopathic features following TNMG may be more common than currently recognized. Fetal AChR inactivation syndrome should be considered in the differential diagnosis of infants presenting with unexplained myopathic features, in particular marked dysarthria and velopharyngeal incompetence. Correct diagnosis requires a high degree of suspicion if the mother is asymptomatic but is crucial considering the high recurrence risk for future pregnancies and the potentially treatable nature of this condition. Infants with a history of TNMG should be followed up for subtle myopathic signs and associated complications.

Neural Neuroimmunol Neuroinflamm 2015;2:e57; doi: 10.1212/NXI.0000000000000057

GLOSSARY

AChR = acetylcholine receptor; AMC = arthrogryposis multiplex congenita; cDNA = complementary DNA; HEK = human embryonic kidney; Ig = immunoglobulin; IV Ig = IV immunoglobulin; MG = myasthenia gravis; MuSK = muscle-specific kinase; TNMG = transient neonatal myasthenia gravis; VPI = velopharyngeal incompetence.

Transient neonatal myasthenia gravis (TNMG) is a rare complication of maternal myasthenia gravis (MG), affecting around 10%–15% of infants of mothers with antibodies to the acetylcholine receptor (AChR) and, less frequently, muscle-specific kinase (MuSK). In the only detailed study, the fetal AChR, a pentameric complex composed of 2 α, 1 β, 1 δ, and 1 γ subunit is present until around 30 weeks, at which time it is replaced by the adult ε subunit.

Infants born to mothers with MG, which is due to antibodies that act on AChRs at the neuromuscular junction, are at risk of TNMG; these antibodies commonly bind to both adult and fetal AChR, which differ in one subunit. Antibodies that selectively inhibit the function of the fetal γ subunit can be associated with severe cases of fetal arthrogryposis. Recently, a persistent myopathy

*These authors contributed equally to this article.

From the Department of Pediatric Neurology (Y.H., S.B., D.C., M.L., H.J.), Evelina’s Children Hospital, Guy’s & St. Thomas’ Hospital NHS Foundation Trust, London, United Kingdom; Department of Clinical Neurology (Y.H., L.W.J., A.V.), Oxford University, Oxford; Department of Neurology (F.N.), Department of Neonatology (A.P.B.), Rigshospitalet, Copenhagen University Hospital, Copenhagen; Department of Pediatrics (A.P.B.), Rigshospitalet, Copenhagen University Hospital, Denmark.

Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the Nuffield Department of Clinical Neuroscience, Oxford University.

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative works 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
During these pregnancies, treatment was mainly aimed at maternal symptom control. Nasogastric tube feeding was required for 10/52 in patient 1.1 and for 6/52 in patient 1.2.

Abbreviations: AMC.

Table 1 Clinical findings in patients with fetal acetylcholine receptor inactivation syndrome

| Family | Patient | Sex | Maternal MG | Maternal treatment | Contractures | Feeding problems | Respiratory problems | Outcome and other features |
|--------|---------|-----|-------------|--------------------|--------------|-----------------|----------------------|---------------------------|
| 1      | 1.1     | F   | No          | No                 | Distal       | Yes             | Yes                  | Mild learning difficulties, unilateral hearing impairment |
| 1      | 1.2     | F   | No          | Yes                | Distal       | Yes             | Yes                  | Similar but less severely affected than sister (1.1); normal development at 4 years |
| 2      | 2.1     | M   | Yes         | Yes*              | AMC          | NA              | NA                   | Gestational diabetes; died postpartum |
| 2      | 2.2     | M   | Yes         | Yes                | No           | Yes             | Yes                  | Facial weakness, mild developmental delay, pyloric stenosis, pyloromyotomy |
| 2      | 2.3     | M   | Yes         | Yes                | Yes          | Yes             | No                   | Similar but less severely affected than brother (2.2); normal developmental milestones |
| 3      | 3.1     | M   | Yes         | Yes*              | No           | Yes             | Yes                  | Died at 17 days |
| 3      | 3.2     | F   | Yes         | Yes*              | No           | Yes             | No                   | Disproportionate facial and bulbar weakness |
| 4      | 4.1     | F   | Yes         | Yes                | Yes          | Yes             | Yes                  | MRI brain at 5 months: delayed myelination, right frontal lobe infarct; died at 5 months |

Abbreviations: AMC = arthrogryposis multiplex congenita; MG = myasthenia gravis; NA = not applicable.

* Nasogastric tube feeding was required for 10/52 in patient 1.1 and for 6/52 in patient 1.2.

** During these pregnancies, treatment was mainly aimed at maternal symptom control.
A combination of pyridostigmine, prednisolone, IV immunoglobulin (IVIg), and 8 cycles of plasma exchange, although AChR antibody titers remained high. A female infant (patient 2.1) was born at 34 weeks with severe and neonatally lethal arthrogryposis multiplex congenital (AMC). The mother had a thymectomy 5 weeks postpartum. Details of her antenatal and perinatal anesthetic management have been previously reported.7

During her second pregnancy, myasthenic symptoms were well-controlled by a combination of plasmapheresis on 3 occasions at the end of the first trimester and IVIg as required. At birth, the male infant (patient 2.2) had hypotonia with poor suck and swallow. He was ventilated for almost 3 weeks but subsequently established and maintained respiratory independence. He was initially tube fed but because of persistent difficulties required intermittent gastrostomy insertion. At 6 weeks corrected age he developed hypertrophic pyloric stenosis. He continues to make developmental progress. He has persistent but improving facial and axial weakness (figure 1, H–K).

During her third pregnancy, maternal myasthenic symptoms were controlled using IVIg until the fifth month. A male infant (patient 2.3) was born by elective cesarean section at 38 weeks and was noted to have paucity of movements and low tone but no contractures. He was transferred to the special care baby unit because of a supplemental oxygen requirement and an inadequate suck and swallow. He was started on pyridostigmine with moderate response. He required additional nasogastric tube feeds because of an inefficient, fatigable suck. He is currently 10 months old and his development is appropriate.

### Table 2: Summary of investigations in patients with fetal acetylcholine receptor inactivation syndrome

| Family | Patient | AChR antibody levels |
|--------|---------|----------------------|
| 1 M     | 3.3 nM  | fetal only           |
| 1.1 ND  |         |                      |
| 1.2 ND  |         |                      |
| 2 M     | 27.9 nM |                      |
| 2.1 ND  |         |                      |
| 2.2     | 30.3 nM |                      |
| 2.3     | ND      |                      |
| 3 M     | 5.6 nM  | fetal > adult ratio 3.0/1.0 |
| 3.1 ND  |         |                      |
| 3.2     | 2.9 nM  | fetal > adult ratio 1.5/0 |
| 4 M     | 2.1 nM  | fetal > adult        |
| 4.1     | ND      |                      |

Abbreviations: AChR – acetylcholine receptor; M – maternal; ND – no data.

Family 3. A 23-year-old woman was diagnosed with MG, and after initial medical treatment she underwent thymectomy followed by symptomatic improvement. At the time of her first pregnancy at 25 years, she was on prednisone 20 mg alternate days and pyridostigmine 60 mg 4 times daily. Reduced fetal movement and polyhydramnios were noted. She delivered a male infant at term (patient 3.1) who had severe hypotonia with respiratory insufficiency, requiring intubation and ventilation. He died at 17 days of age from respiratory failure.

Two years later she became pregnant again. Her myasthenic symptoms had improved on a reduced dose of prednisolone 10 mg alternate days. She had polyhydramnios but fetal movements were normal. A female infant (patient 3.2) was born at 38 weeks with hypotonia, respiratory distress, and generalized weakness. Following initial nasogastric tube feeding, she underwent gastrostomy placement at 7 months. Neonatal MG was diagnosed based on the detection of circulating antibodies that bound preferably to the fetal AChR (γ subunit) rather than the adult AChR (ε subunit) in both mother and infant (figure 2; table 2). The infant improved slowly but had persistent bulbar and facial weakness. No additional benefit was gained from immunotherapy and pyridostigmine treatment. A muscle biopsy taken at 7 months from the quadriceps was normal. Nerve conduction studies were normal but EMG showed myopathic changes, in particular in the facial muscles. At 20 months of age, she has made developmental progress and her bulbar function has improved, but her nasal speech and facial paresis remain severe.

Family 4. A 26-year-old primagravida with known MG was treated with high-dose pyridostigmine only during pregnancy. At 27 weeks’ gestation, polyhydramnios was detected, requiring therapeutic amniocentesis. A course of plasmapheresis with 7 exchanges resulted in a decrease in maternal AchR antibody levels. Because of signs of fetal distress, a female infant (patient 4.1) was delivered by emergency cesarean section at 31 + 5 weeks’ gestation. Birth weight was 1.545 kg. She was profoundly hypotonic and required intubation and ventilation. A trial of neostigmine showed no effect on respiration, but both muscle tone and antigravity movements improved. On examination, she had hypotonia, weakness, contractures of the third to fifth fingers bilaterally, and mild tightness of the hip adductors. At 8 weeks she was extubated but remained dependent on facial oxygen and/or nasal continuous positive airway pressure. She was never able to swallow saliva or fluids, but limb strength remained relatively good. Therapeutic trials with

---

**Neurology: Neuroimmunology & Neuroinflammation**

© 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
IVIg and pyridostigmine were ineffective. EMG studies including repetitive nerve stimulation in the extremities were normal. At 4 months, she required reintubation and 2 weeks of ventilator support. In accordance with parental wishes it was decided not to reintubate her in case of further deterioration, and she eventually died at 5 months of age from respiratory failure.

In the index case from family 1 (A–D), there is a myopathic facial appearance with a horizontal smile but no ptosis. Her younger sister (E–G) was less severely affected and had only mild facial weakness as well as mild finger flexion deformities. The first surviving sibling in family 2 (H–K) had marked facial weakness with an inverted V-shaped mouth and bilateral ptosis. He made good developmental progress but had persistent axial weakness that slowly improved over time.

The fetal (gamma subunit specific) and adult (epsilon subunit specific) forms of the receptors were expressed in human embryonic kidney cells, identified with green fluorescence. Binding of immunoglobulin G was detected by anti-human IgG (red fluorescence). Results of a maternal serum from patient 3 that bound very weakly to the adult receptor (A), but strongly to the fetal receptor (B).
DISCUSSION  TNMG results from placental transfer of maternal antibodies and usually remits spontaneously over days to weeks. However, in rare cases the disorder persists and leaves the child with permanent disability, either multiple joint contractures (AMC) or myopathic features. Here we describe the first small case series of 8 children from 4 families with persistent myopathy and a history of either maternal MG or asymptomatically elevated maternal AChR antibody levels. These cases illustrate the persistent and potentially severe disability that can result from maternal AChR antibody exposure in utero and the possibility that better prenatal and perinatal surveillance and treatments may improve outcomes.

TNMG has been associated with antibodies to both the AChR and, very occasionally, MuSK. There is no correlation to maternal disease severity or absolute maternal antibody levels, but TNMG tends to recur in further pregnancies. Maternal thymectomy appears to have a protective effect. TNMG is usually transient, but persistent myopathic manifestations have been reported in a few isolated cases, previously thought to be due to coexisting pathology.

Within our cohort, at the most severe end of the spectrum infants presented with marked arthrogryposis and profound respiratory impairment resulting in early death, whereas the mildest cases had normal developmental milestones and only mild weakness, mainly affecting the facial and bulbar muscles. Severity of clinical symptoms in affected infants appeared to be related to the timing, intensity, and frequency of maternal treatment, as demonstrated in families 1, 2, and 3, in which fetal outcomes were better following optimization of maternal treatment and control of maternal symptoms, corresponding to earlier observations in isolated families. Control in subsequent pregnancies was easier to attain following maternal thymectomy in family 2. However, the relatively severe phenotype in family 4 suggests that fetal outcome may only be partly modified by optimal maternal treatment. With the exception of those who died early, the clinical course was characterized by an initial period of profound hypotonia, bulbar and respiratory impairment for several weeks, and continuous improvement but variable persistent myopathic features over subsequent years. The course in these patients suggests 2 distinct pathogenic mechanisms causing first an acute phase due to a transient neuromuscular transmission defect and second a chronic phase due to permanent myopathic damage; the latter observation would be consistent with an absent response to immunomodulatory/anticholinergic treatments and lack of evidence for a neuromuscular transmission defect in the chronic phase of the condition.

Marked dysarthria with or without velopharyngeal incompetence (VPI) was one of the most prominent persistent features observed in our series and also by others. It is interesting that TNMG has been reported as an identifiable factor in the medical history in a large cohort of patients with VPI, indicating a possible association. Pyloric stenosis was a feature in one of our patients and has previously been reported in an isolated case with TNMG; it is uncertain whether this association reflects a shared disease mechanism and/or the effects of anticholinergic treatment. One patient each had mild learning difficulties and delayed myelination, but larger series will be required to identify whether mild CNS involvement is part of the phenotypical spectrum or reflective of dual pathology. Lastly, hearing impairment was present in the index case in family 1 and was previously reported in one family with fetal AChR inactivation syndrome but also in surviving children with AMC. The relevance of these observations and the pathophysiology of the hearing loss are not clear yet, bearing in mind that neuronal AChRs are structurally similar but not identical to muscle AChRs.

Maternal antibodies to AChRs were the defining feature in all 4 families, in 2 cases binding more strongly to the γ subunit containing fetal AChRs than to the ε subunit containing adult AChRs. It was suggested that, despite considerable variability in absolute AChR antibody levels, the anti-α/anti-ε AChR antibody titer ratio remains relatively stable and can predict fetal outcome, but exceptions have been reported. Recently, a more appropriate cell-based assay for the detection of AChR antibodies binding to extracellular AChR epitopes on live HEK cells has been developed and can be used to measure the fetal and adult AChR antibodies independently. However, the binding of antibodies to fetal AChRs does not necessarily indicate the subgroup of fetal-specific antibodies that might cause paralysis in vivo, particularly those that inhibit AChR function. Moreover, it is possible that complement-mediated damage is also involved, as was demonstrated in one case of AMC, suggesting that different pathogenic mechanisms, perhaps acting at different times in gestation, may be relevant.

Our findings suggest a continuum between diverse disorders previously associated with maternal antibodies to the fetal AChR γ subunit, namely a subgroup of AMC and the more recently described “fetal AChR inactivation syndrome.” AMC is defined by multiple fixed joints, usually resulting from intratertiary lack of movement, and is caused by a wide range of different environmental or genetic factors, many of which are still unknown. High levels of maternal antibodies to the fetal AChR γ subunit were initially identified in rare cases of AMC, often recurring in
successive pregnancies and not always associated with evidence of maternal MG, corresponding to family 1 in which the mother was also asymptomatic. High titers of antibodies specifically blocking the function of the fetal AChR γ subunit are rare in “classical” MG, explaining why AMC, although present in the most severe cases within our series, is generally uncommon in babies born to mothers with typical MG. At the milder end of the spectrum, our patients shared many findings with the “fetal AChR inactivation syndrome” described by Oskoui et al.5 in a family with 3 affected males, featuring facial diplegia but preserved strength in the limbs, high arched palate, VPI, hearing loss, and cryptorchidism. A similar isolated case has been reported more recently,6 indicating that long-term myopathic sequelae of TNMG are probably more common than currently recognized. We propose that “fetal AChR inactivation syndrome” comprises a wide range of manifestations, depending on both maternal antibodies to the fetal AChR γ subunit and modifying factors such as the timing, intensity, and frequency of maternal treatment.

The pivotal role of the AChR γ subunit in the pathogenesis of the phenotype reported in this article is supported by observations in various animal models and related inherited human disorders. During normal embryonic development, the fetal AChR helps to establish the primary connection between muscle and the nerve axon and is likely to be important not only for neuromuscular signal transduction but also for neuromuscular organogenesis,19 a hypothesis supported by the lethal phenotype in AChR γ subunit knockout mice.20 Moreover, patients with Escobar syndrome (Online Mendelian Inheritance in Man # 265000) secondary to mutations in the CHRNγ gene encoding the AChR γ subunit21 typically present with joint contractures, excess webbing (“pterygia”), and respiratory distress. In contrast to congenital myasthenic syndromes secondary to mutations in genes encoding the α, β, and ε AChR subunits, which are expressed postnatally, patients with Escobar syndrome have no myasthenic symptoms later in life; this corresponds to observations in our own series, in which neurophysiologic assessments did not reveal any evidence for a persistent neuromuscular transmission defect and anticholinergic treatment was uniformly ineffective in the chronic stages of the condition. The persistent features observed in our patients are therefore most likely to reflect the effects of a prenatal exposure to antibodies that cause a fetal hypokinesia sequence, including an irreversible endplate myopathy corresponding to findings in antibody-mediated AMC,18 rather than an ongoing neuromuscular transmission defect.

While neonatal MG is mostly transient, maternal antibodies against the AChR γ subunit may cause persistent myopathic features in a subset of affected infants. Correct diagnosis requires a high degree of suspicion if the mother is asymptomatic but is crucial considering the high recurrence risk for future pregnancies and the essentially treatable nature of this condition. Fetal AChR inactivation syndrome should be considered in the differential diagnosis of infants presenting with unexplained myopathic features, in particular marked dysarthria and VPI, even in the absence of maternal symptoms. Lastly, infants with a history of TNMG should be followed up for signs of dysarthria or hearing impairment, as those may be subtle but at least partially amenable to supportive management.

**AUTHOR CONTRIBUTIONS**

Yael Hacohen: obtaining, analysis, and interpretation of the data, drafting the manuscript. Leslie W. Jacobson: obtaining, analysis, and interpretation of the data, drafting the manuscript. Susan Byrne: obtaining the data, drafting the manuscript. Fiona Norwood: obtaining, analysis, and interpretation of the data, revising the manuscript. Abhimanu Lall: obtaining the data, revising the manuscript. Stephanie Robb: obtaining, analysis, and interpretation of the data, revising the manuscript. Robertino Dilella: obtaining, analysis, and interpretation of the data, revising the manuscript. Monica Fumigalli: obtaining the data, revising the manuscript. Alfred Peter Born: obtaining, analysis, and interpretation of the data, revising the manuscript. Debbie Clarke: revising the manuscript. Ming Lim: design of the study, interpretation of the data, revising the manuscript. Angela Vincent: design of the study, interpretation of the data, revising the manuscript. Heinz Jungbluth: design of the study, interpretation of the data, revising the manuscript.

**STUDY FUNDING**

No targeted funding reported.

**DISCLOSURE**

Y. Hacohen received research support from NIHR. L.W. Jacobson, S. Byrne, F. Norwood, A. Lall, S. Robb, R. Dilella, and M. Fumigalli report no disclosures. A.P. Born is an associate editor for *Acta Paediatrica* and received research support from GlaucomaSmithKline. D. Clarke reports no disclosures. M. Lim has received travel grants from Merck Serono, consulted for CSL Behring, and received research support from Action Medical Research, MS Society UK, SPARKS Charity, GOSH, and DES. A. Vincent has received honoraria from Baxter International Inc. and Biogen Inc.; is on the editorial board for *Neurology*; is an associate editor for *Brain*; holds a patent with Oxford University for VGKC complex antibodies; receives royalties from Athena Diagnostics, Euroimmun AG, Blackwell Publishing, and Mac Keith Press; consulted for Athena Diagnostics; and received research support from NIHR. H. Jungbluth is an editorial board member for *Neuromuscular Disorder*, *MBC Paediatrics*, and *Journal of Neuromuscular Disease* and received research support from Guy’s and St. Thomas’ Hospital Charitable Foundation. Go to Neurology.org/nm for full disclosures.

Received July 6, 2014. Accepted in final form November 3, 2014.

**REFERENCES**

1. Vernet-der Garabedian B, Lacokova M, Eymard B, et al. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. *J Clin Invest* 1994; 94:555–559.
2. Nils EH, Verrips A, Semmekrot BA, et al. A transient neonatal myasthenic syndrome with anti-musk antibodies. *Neurology* 2008;70:1215–1216.
3. Hesselmans LF, Jennekens FG, Van den Oord CJ, Veldman H, Vincent A. Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors. Anat Rec 1993;236:553–562.

4. Vincent A, Newland C, Brueton L, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24–25.

5. Osouki M, Jacobson L, Chung WK, et al. Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology 2008;71:2010–2012.

6. D’Amico A, Berini E, Bianco F, et al. Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: a case report. Neuromuscul Disord 2012;22:546–548.

7. Chieza JT, Fleming I, Panny N, Skelton VA. Maternal myasthenia gravis complicated by fetal arthrogryposis multiplex congenita. Int J Obstet Anesth 2011;20:79–82.

8. Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 2014;85:538–543.

9. Hoff JM, Dalvie AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007;14:38–43.

10. Morel E, Eymard B, Vernet-der Garabedian B, Pannier C, Dulac O, Bach JF. Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 1988;38:138–142.

11. Ahlsten G, Lefvert AK, Osterman PO, Stalberg E, Safwenberg J. Follow-up study of muscle function in children of mothers with myasthenia gravis during pregnancy. J Child Neurol 1992;7:264–269.

12. Rieder AA, Conley SF, Rowe L. Pediatric myasthenia gravis and velopharyngeal incompetence. Int J Pediatr Otorhinolaryngol 2004;68:747–752.

13. Jeannet PY, Marcoz JP, Kuntzer T, Roulet-Perez E. Isolated facial and bulbar paresis: a persistent manifestation of neonatal myasthenia gravis. Neurology 2008;70:237–238.

14. Regenbaum S, Sidhu K, Smith CE. Transient neonatal myasthenia gravis and pyloric stenosis. J Clin Anesth 1995;7:515–518.

15. Gardnerova M, Eymard B, Morel E, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 1997;48:50–54.

16. Leite MI, Jacob S, Vegas S, et al. IgG1 antibodies to acetylcholine receptors in “seronegative” myasthenia gravis. Brain 2008;131:1940–1952.

17. Riemersma S, Vincent A, Beeson D, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98:2358–2363.

18. Reimann J, Jacobson L, Vincent A, Kornblum C. Endplate destruction due to maternal antibodies in arthrogryposis multiplex congenita. Neurology 2009;73:1806–1808.

19. Koenen M, Peter C, Villarroel A, Witzemann V, Sakmann B. Acetylcholine receptor channel subtype directs the innervation pattern of skeletal muscle. EMBO Rep 2005;6:570–576.

20. Takahashi M, Kubo T, Mizoguchi A, Carlson CG, Endo K, Ohnishi K. Spontaneous muscle action potentials fail to develop without fetal-type acetylcholine receptors. EMBO Rep 2002;3:674–681.

21. Hoffmann K, Muller JS, Stricker S, et al. Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. Am J Hum Genet 2006;79:303–312.
Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies
Yael Hacohen, Leslie W. Jacobson, Susan Byrne, et al.
Neurol Neuroimmunol Neuroinflammm 2015;2;
DOI 10.1212/NXI.0000000000000057

This information is current as of December 23, 2014